Treatment of Ventilator-Associated Pneumonia Caused by Acinetobacter baumannii

Initial Assessment and Treatment

The Infectious Diseases Society of America recommends using intravenous polymyxin (colistin or polymyxin B) as the backbone of therapy for VAP caused by Acinetobacter baumannii, with adjunctive inhaled colistin for carbapenem-resistant strains, and a carbapenem or ampicillin-sulbactam as first-line therapy for carbapenem-susceptible isolates 1
The American Thoracic Society suggests obtaining lower respiratory tract cultures via bronchoscopic or non-bronchoscopic methods before initiating definitive therapy, but not delaying antibiotic initiation in critically ill patients 2

For carbapenem-susceptible Acinetobacter baumannii, the Infectious Diseases Society of America recommends using either a carbapenem (imipenem 0.5-1g every 6 hours or meropenem 2g every 8 hours via extended infusion) or ampicillin-sulbactam as first-line therapy 1
For carbapenem-resistant Acinetobacter baumannii, the Infectious Diseases Society of America recommends intravenous polymyxin therapy (strong recommendation) with colistin or polymyxin B as the backbone of treatment 1
The Infectious Diseases Society of America suggests using adjunctive inhaled colistin (weak recommendation) to improve clinical outcomes by achieving higher drug concentrations at the infection site 1, 3

The Infectious Diseases Society of America recommends considering sulbactam-based regimens as an alternative treatment option, with sulbactam demonstrating intrinsic activity against Acinetobacter species 4
The Infectious Diseases Society of America suggests using minocycline in combination with another active agent rather than as monotherapy for serious infections 4

The Infectious Diseases Society of America recommends avoiding tigecycline monotherapy for VAP caused by Acinetobacter baumannii due to poor outcomes and low concentrations in endothelial lining fluids 1, 4
The American Thoracic Society suggests avoiding aminoglycoside monotherapy for Acinetobacter infections, but allowing its use in combination therapy for 5-7 days in responding patients 1, 5

The Infectious Diseases Society of America recommends treating for 7 days if the patient has a good clinical response with resolution of clinical features of infection, but extending therapy to 2 weeks (10-14 days) for severe infections manifested as severe sepsis or septic shock 1, 3, 5

The Infectious Diseases Society of America suggests performing therapeutic drug monitoring whenever possible when using polymyxins to optimize dosing and minimize toxicity 6
The American Thoracic Society recommends regular monitoring of renal function when using polymyxins, as nephrotoxicity rates can reach 57% with colistin-based regimens 7

The Infectious Diseases Society of America recommends using IV ampicillin-sulbactam as first-line therapy for VAP caused by Acinetobacter in patients with acute kidney injury, if the isolate is susceptible, due to its comparable efficacy to colistin with significantly lower nephrotoxicity risk 8, 9
For carbapenem-susceptible Acinetobacter, the American Thoracic Society suggests using either imipenem or meropenem, but in AKI patients, ampicillin-sulbactam is preferred to minimize further renal injury 8, 9
The European Respiratory Society recommends using high-dose ampicillin-sulbactam for carbapenem-resistant but sulbactam-susceptible Acinetobacter, as it demonstrates comparable efficacy to colistin with a better renal safety profile 9

The Kidney Disease: Improving Global Outcomes initiative notes that colistin carries a significant nephrotoxicity risk, whereas ampicillin-sulbactam demonstrates significantly lower nephrotoxicity 9
The National Kidney Foundation recommends performing renal dose adjustments for colistin based on creatinine clearance, and monitoring renal function closely 10, 11

The Infectious Diseases Society of America suggests using combination therapy if the patient remains in septic shock or at high risk of death when susceptibility results are known, and recommends against using tigecycline for VAP due to Acinetobacter 8, 10
The American Thoracic Society recommends treating for 7 days if there is a good clinical response, but extending to 10-14 days for severe infections with septic shock or high mortality risk 8, 10

The European Respiratory Society recommends daily serum creatinine and renal function assessment when using polymyxins, and monitoring for clinical response at 72 hours, day 7, and day 28 9
The Society of Critical Care Medicine advises against delaying appropriate empiric therapy, using standard vancomycin doses for gram-positive coverage, and continuing combination therapy if septic shock resolves 8, 12

Septic‑shock patients require dual Gram‑negative coverage plus MRSA therapy when ≥ 25 % of Staphylococcus aureus isolates in the ICU are MRSA – European Respiratory Society recommendation. 13
When ICU prevalence of resistant Acinetobacter exceeds 25 %, broad empiric antimicrobial coverage is mandated – European Respiratory Society recommendation. 13, 14
For high‑risk patients who are not in septic shock but are in ICUs with high Acinetobacter prevalence, the second agent in dual‑pseudomonal therapy should be colistin rather than an aminoglycoside or fluoroquinolone – European Respiratory Society recommendation. 13

Maintain combination therapy only for extensively drug‑resistant (XDR) or pan‑drug‑resistant (PDR) Acinetobacter infections and for carbapenem‑resistant Enterobacteriaceae – European Respiratory Society recommendation (strong). 14
De‑escalate to monotherapy after 3–5 days if the initial regimen was appropriate, the patient’s clinical course is favorable, and the isolate is not XDR/PDR – European Respiratory Society recommendation (moderate). 13
Do not continue combination therapy after septic‑shock resolution when susceptibility data show a non‑XDR organism – European Respiratory Society recommendation. 13, 14